sales@reportocean.com (Bussiness Sales)
+18882123539 (Us - Toll Free)
+919997112116 (Rest Of World)
Global Myocardial Infarction Therapeutics Market Size Study, by Therapeutic Class, by Route of Administration, by Indication, by Mechanism of Action and Regional Forecasts 2024-2032

Global Myocardial Infarction Therapeutics Market Size Study, by Therapeutic Class,...

Home / Categories / Healthcare
Global Myocardial Infarction Therapeutics Market Size Study, by Therapeutic Class, by Route of Administration, by Indication, by Mechanism of Action and Regional Forecasts 2024-2032
Global Myocardial Infarction Therapeutics Market...
Report Code
RO1/103/3198

Publish Date
16/Oct/2024

Pages
200
PRICE
$ 1800/-
This is a single user license, allowing one specific user access to the product. The product is a PDF.
$ 2350/-
This is a 1-5 user license, allowing up to five users have access to the product. The product is a PDF.
$ 2850/-
This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF..
Table of Contents
Chapter 1. Global Myocardial Infarction Therapeutics Market Executive Summary
1.1. Global Myocardial Infarction Therapeutics Market Size & Forecast (2024-2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Therapeutic Class
1.3.2. By Route of Administration
1.3.3. By Indication
1.3.4. By Mechanism of Action
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Myocardial Infarction Therapeutics Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer's Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory Frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global Myocardial Infarction Therapeutics Market Dynamics
3.1. Market Drivers
3.1.1. Rising Prevalence of Cardiovascular Diseases
3.1.2. Technological Advancements in MI Treatment
3.1.3. Increasing Healthcare Expenditure
3.2. Market Challenges
3.2.1. High Cost of Treatment
3.2.2. Limited Accessibility in Developing Regions
3.3. Market Opportunities
3.3.1. Development of Novel Treatments
3.3.2. Adoption of Telemedicine and Remote Patient Monitoring
3.3.3. Shift Towards Minimally Invasive Procedures
Chapter 4. Global Myocardial Infarction Therapeutics Market Industry Analysis
4.1. Porter's 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter's 5 Force Model
4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunity
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Myocardial Infarction Therapeutics Market Size & Forecasts by Therapeutic Class 2024-2032
5.1. Segment Dashboard
5.2. Global Myocardial Infarction Therapeutics Market: Therapeutic Class Revenue Trend Analysis, 2022 & 2032 (USD Billion)
5.2.1. Antiplatelet Agents
5.2.2. Antithrombotic Agents
5.2.3. Nitrates
5.2.4. Calcium Channel Blockers
5.2.5. Lipid-Lowering Agents
Chapter 6. Global Myocardial Infarction Therapeutics Market Size & Forecasts by Route of Administration 2024-2032
6.1. Segment Dashboard
6.2. Global Myocardial Infarction Therapeutics Market: Route of Administration Revenue Trend Analysis, 2022 & 2032 (USD Billion)
6.2.1. Oral
6.2.2. Intravenous
6.2.3. Subcutaneous
6.2.4. Transdermal
Chapter 7. Global Myocardial Infarction Therapeutics Market Size & Forecasts by Indication 2024-2032
7.1. Segment Dashboard
7.2. Global Myocardial Infarction Therapeutics Market: Indication Revenue Trend Analysis, 2022 & 2032 (USD Billion)
7.2.1. ST-Elevation Myocardial Infarction (STEMI)
7.2.2. Non-ST-Elevation Myocardial Infarction (NSTEMI)
7.2.3. Unstable Angina
Chapter 8. Global Myocardial Infarction Therapeutics Market Size & Forecasts by Mechanism of Action 2024-2032
8.1. Segment Dashboard
8.2. Global Myocardial Infarction Therapeutics Market: Mechanism of Action Revenue Trend Analysis, 2022 & 2032 (USD Billion)
8.2.1. Platelet Aggregation Inhibitors (P2Y12 Inhibitors, GPIIb/IIIa Inhibitors)
8.2.2. Thrombin Inhibitors
8.2.3. Anticoagulants
8.2.4. Calcium Channel Blockers
8.2.5. HMG-CoA Reductase Inhibitors
Chapter 9. Global Myocardial Infarction Therapeutics Market Size & Forecasts by Region 2024-2032
9.1. North America Myocardial Infarction Therapeutics Market
9.1.1. U.S. Myocardial Infarction Therapeutics Market
9.1.1.1. Therapeutic Class Breakdown Size & Forecasts, 2024-2032
9.1.1.2. Route of Administration Breakdown Size & Forecasts, 2024-2032
9.1.1.3. Indication Breakdown Size & Forecasts, 2024-2032
9.1.1.4. Mechanism of Action Breakdown Size & Forecasts, 2024-2032
9.1.2. Canada Myocardial Infarction Therapeutics Market
9.2. Europe Myocardial Infarction Therapeutics Market
9.2.1. U.K. Myocardial Infarction Therapeutics Market
9.2.2. Germany Myocardial Infarction Therapeutics Market
9.2.3. France Myocardial Infarction Therapeutics Market
9.2.4. Spain Myocardial Infarction Therapeutics Market
9.2.5. Italy Myocardial Infarction Therapeutics Market
9.2.6. Rest of Europe Myocardial Infarction Therapeutics Market
9.3. Asia-Pacific Myocardial Infarction Therapeutics Market
9.3.1. China Myocardial Infarction Therapeutics Market
9.3.2. India Myocardial Infarction Therapeutics Market
9.3.3. Japan Myocardial Infarction Therapeutics Market
9.3.4. Australia Myocardial Infarction Therapeutics Market
9.3.5. South Korea Myocardial Infarction Therapeutics Market
9.3.6. Rest of Asia Pacific Myocardial Infarction Therapeutics Market
9.4. Latin America Myocardial Infarction Therapeutics Market
9.4.1. Brazil Myocardial Infarction Therapeutics Market
9.4.2. Mexico Myocardial Infarction Therapeutics Market
9.4.3. Rest of Latin America Myocardial Infarction Therapeutics Market
9.5. Middle East & Africa Myocardial Infarction Therapeutics Market
9.5.1. Saudi Arabia Myocardial Infarction Therapeutics Market
9.5.2. South Africa Myocardial Infarction Therapeutics Market
9.5.3. Rest of Middle East & Africa Myocardial Infarction Therapeutics Market
Chapter 10. Competitive Intelligence
10.1. Key Company SWOT Analysis
10.2. Top Market Strategies
10.3. Company Profiles
10.3.1. Bristol-Myers Squibb Company
10.3.1.1. Key Information
10.3.1.2. Overview
10.3.1.3. Financial (Subject to Data Availability)
10.3.1.4. Product Summary
10.3.1.5. Market Strategies
10.3.2. Boehringer Ingelheim International GmbH
10.3.3. Merck & Co., Inc.
10.3.4. Teva Pharmaceutical Industries Ltd.
10.3.5. Abbott Laboratories
10.3.6. Novartis AG
10.3.7. Sanofi Aventis US, LLC
10.3.8. AstraZeneca plc
10.3.9. Pfizer Inc.
10.3.10. Roche Holding AG
10.3.11. Bayer AG
10.3.12. Eli Lilly and Company
10.3.13. Johnson & Johnson
Chapter 11. Research Process
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes

OUR CLIENTS

500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, UNITED STATES
+18882123539
sales@reportocean.com